Lebrikizumab demonstrates efficacy in atopic dermatitis and skin of color patients in first of its kind study
Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options for adolescents with moderate-to-severe disease. Lebrikizumab is a monoclonal antibody targeting interleukin (IL)-13. Researchers have found in first of its kind study that Lebrikizumab was associated with clinical benefit among patients atopic dermatitis and skin of color. In this study, treatment with […]